From April 9th to 11th, 2025, Sichuan Xieli Pharmaceutical Co., Ltd, participated in the CPHI Japan held in Tokyo. It joined nearly 20,000 pharmaceutical industry peers from over 20 countries around the world to showcase, exchange ideas, and discuss the future development blueprint. As an API enterprise with over 40 years of experience in the production of natural APIs and raw materials for food and health products, Xieli Pharm exhibited a number of its flagship products, ongoing R&D projects, and future market plans for Kampo medicine, demonstrating the company's growing R&D strength in the international pharmaceutical market and its market plan for expanding global exports.
During the exhibition, the company's team actively presented its core API product lines, progress of R&D pipelines, and the whole industrial chain service system, comprehensively demonstrating the company's systematic competitiveness from R&D to production. Through product introductions and technical solution explanations by the team at the booth, Xieli conveyed its core values in quality control, technological innovation, and compliant operation to global customers.
In this exhibition, Xieli Pharm also highlighted its R&D and production capabilities in the field of Kampo medicine. As an important carrier for the internationalization of traditional Chinese medicine, Kampo medicine has a wide range of recognition and development potential in the Japanese and East Asian markets. Relying on mature production processes, standardized quality standards, and a continuously optimized raw material traceability system, Xieli Pharm has established an internationally registered Kampo medicine production platform, attracting the attention and inquiries of many customers on-site.
A plenty of visiting customers reprobate the company's in-depth specialization and large-scale supply capabilities in the field of specialty APIs highly matched their global procurement needs. The team had deep discussions with new and regular customers, accurately grasping the current trend in the international market, which is shifting from single-product demands to comprehensive-ability assessments. Many customers emphasized during the communication that, in addition to strict product quality standards, the supplier's supply-chain resilience, price-system transparency, and service-response efficiency have become key decision-making factors. In response, the company's team, based on the actual needs of customers, focused on introducing its advanced production system, excellent supply strategies, and customized service solutions. This showed the company's supply-chain stability, cost-control capabilities, and service efficiency, and won high attention from visiting customers. Customers expressed their intention for further cooperation on the spot and jointly explored sustainable cooperation paths.
The booth was constantly crowded with people. There were not only new customers who came to consult and negotiate out of admiration but also old customers who made special trips for communication and interaction. Many international customers who had cooperated with the company for years specifically came to learn about the company's latest R&D trends and market plans and recognized the company's continuously improved service efficiency. The two sides had practical discussions on industry trends, regional market dynamics, and potential cooperation opportunities, laying a good foundation for further deepening strategic cooperation in the future.
Facing the increasingly complex international trade environment in recent years, Xieli Pharm has always adhered to the business philosophy of "oriented by customer needs", continuously optimized its supply-chain layout and service-response mechanism, and demonstrated its comprehensive strength in flexibly responding to market demands. This exhibition not only provided the company with a platform for in-depth dialogue with peers in the Japanese market and valuable experience in dealing with the complex trade situation in recent years but also, through directly facing market feedback, further clarified the upgrade direction of its globalization strategy.
In the future, Xieli Pharm will continue to adhere to the development direction of specialization and internationalization, continuously deepen its efforts in the fields of APIs and Kampo medicine, and promote the dual optimization of its product and service systems. The company will take more stable and practical steps to continuously expand overseas market cooperation opportunities and improve its ability to provide high-quality solutions for global customers.
